.svg)
IN THIS EPISODE
In this episode of the Research Forward podcast, host David Mayo interviews Professor Ralf Weiskirchen, a leading expert in liver diseases and head of the Institute of Molecular Pathobiochemistry at RWTH University Hospital Aachen. They delve into the complexities of liver fibrosis, discussing its various causes, including alcohol, viral hepatitis, and genetic diseases. Professor Weiskirchen explains the biochemical processes behind liver fibrosis and the potential for reversing the condition through lifestyle changes and medical interventions.
The conversation also covers the importance of biomarkers for early diagnosis and risk stratification, as well as the promising advancements in gene therapy and CRISPR technology for treating liver diseases. Additionally, they explore the shift towards non-animal models for liver disease research, emphasizing the ethical and practical benefits of using cell lines and organoid models.
A significant portion of the discussion is dedicated to the critical issue of cell line authentication in research. Professor Weiskirchen highlights the prevalence of misidentified cell lines and the impact this has on scientific reproducibility. He advocates for stringent authentication practices, such as STR profiling and NGS sequencing, to ensure the integrity of research data.
About Professor Ralf Weiskirchen
Ralf Weiskirchen is a distinguished academic and researcher in the field of molecular pathobiochemistry, with a particular focus on liver diseases. He was born on February 2, 1964, in Bergisch Gladbach, North Rhine-Westphalia, Germany. His educational journey began at the University of Cologne, where he studied Biology from 1983 to 1989. He completed his diploma thesis at the Institute of Biochemistry and earned his PhD in 1994 with summa cum laude honors for his doctoral thesis at the same institution.
Academic and Professional Journey
After obtaining his PhD, Weiskirchen worked as a research assistant at the Institute of Clinical Chemistry at the University Hospital of Cologne from 1989 to 1990. He then moved to Austria, where he served as a postdoctoral researcher at the Institute of Biochemistry at the University of Innsbruck from 1994 to 1999. Upon returning to Germany, he joined the Institute of Clinical Chemistry and Pathobiochemistry at RWTH Aachen University in 1999.
In 2001, Weiskirchen completed his habilitation in Pathobiochemistry and Molecular Biology, which qualified him to teach at the university level. By 2007, he had been appointed as a full professor and subsequently became the head of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy, and Clinical Chemistry (IFMPEGKC) at RWTH University Hospital Aachen in 2014.
Research Focus
- Weiskirchen's research is centered on understanding the molecular mechanisms underlying hepatic diseases, particularly focusing on:
- Hepatic Fibrogenesis: He investigates critical signaling pathways such as TGF-β (Transforming Growth Factor-beta) and PDGF (Platelet-Derived Growth Factor) that play significant roles in liver fibrosis.
- Therapeutic Strategies: His work involves developing novel therapeutic approaches for liver fibrosis, including gene therapy techniques that target hepatic stellate cells.
- Biomarker Development: Weiskirchen is actively engaged in identifying new biomarkers for liver diseases that can aid in assessing disease severity and treatment response.
- Animal Models: He characterizes animal models for studying organ fibrosis to better understand disease mechanisms and test potential therapies.
Weiskirchen's research has led to over 550 publications in peer-reviewed journals, contributing significantly to the field. His work is highly cited, reflected in his h-index of 65, indicating substantial influence within the scientific community. He has also been recognized as one of the Highly Cited Researchers by Clarivate Analytics.
Collaborations and Contributions
Professor Weiskirchen maintains extensive collaborations with national and international research institutions focusing on molecular aspects of hepatic disease pathogenesis and therapy. His studies are supported by various organizations, including the German Research Foundation (DFG) and German Cancer Aid.
He is an active member of several professional organizations, including the German Association for the Study of the Liver (GASL) and the European Association for the Study of the Liver (EASL). Additionally, he serves on editorial boards for several scientific journals, contributing to advancing research in hepatology.